- ROUNDTABLE: Pharmacy’s future in sync with technology
- NCPA: Community pharmacy has historically helped patients as they transition to new health plans
- ROUNDTABLE: Improving patient outcomes, controlling costs with OTCs
- Study: Limiting NPs' scope of practice leads to higher costs
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
PRINCETON, N.J. Drug maker Angelini Labopharm has launched a new treatment for depression.
The company announced Tuesday the launch of Oleptro (trazodone hydrochloride) extended-release tablets, a once-daily treatment for major depressive disorder. The drug received approval from the Food and Drug Administration in February.
“Oleptro offers physicians another therapeutic alternative for treatment their patients with major depressive disorder,” Angelini Labopharm acting chief medical officer Jeffrey Dayno said. “This is important because we know that patients with MDD present unique profiles and respond differently to treatment – physicians appreciate options to better individualize patient care.”